What is Artiva?
Founded in 2019 and headquartered in San Diego, California, Artiva Biotherapeutics is a private biotechnology enterprise dedicated to the development of off-the-shelf, allogeneic Natural Killer (NK) cell therapies. By leveraging a sophisticated manufacturing platform, the company aims to provide scalable, potent, and accessible treatment options for patients suffering from complex hematologic malignancies and solid tumors. Artiva's operational model focuses on the intersection of molecular biology and clinical scalability, positioning the firm as a high-growth entity within the broader life sciences sector.
How much funding has Artiva raised?
Artiva has raised a total of $198M across 2 funding rounds:
Series A
$78M
Series B
$120M
Series A (2020): $78M with participation from 5AM Ventures, RA Capital Management LP, MEDIVATE PARTNERS LLC, GC LabCell, and venBio Partners LLC
Series B (2021): $120M led by Cormorant Asset Management, Acuta Capital Partners, Franklin Templeton, EcoR1 Capital, and Venrock Healthcare Capital Partners
Key Investors in Artiva
Cormorant Asset Management
A prominent life sciences investment firm with over $3B in assets under management, specializing in fundamental scientific principles to support innovative biotech companies.
Franklin Templeton
A global investment management organization providing specialized expertise across multiple asset classes, including venture capital and private equity for the healthcare sector.
EcoR1 Capital
A San Francisco-based investment fund focused on the biotech sector, dedicated to building long-term partnerships with entrepreneurs advancing therapeutic innovation.
What's next for Artiva?
Looking ahead, Artiva Biotherapeutics is poised to leverage its recent financing to accelerate its clinical trial milestones and expand its manufacturing capabilities. The strategic focus remains on validating the efficacy and safety of its allogeneic NK cell candidates, which are designed to overcome the limitations of traditional autologous therapies. As the company moves deeper into its clinical pipeline, the emphasis will likely shift toward establishing key partnerships and preparing for potential regulatory submissions. The continued support from institutional investors suggests a long-term commitment to scaling the company's platform, with the ultimate goal of delivering transformative therapeutic solutions to the global oncology market.
See full Artiva company page
